We examined the percentages of CD3+, CD3+CD4+, CD3+CD8+, CD14+, and CD3-CD16+CD56+ cells in PBMC samples from 520 cancer patients and 109 healthy individuals, as well as the factors that affected them. This evidence concerns the gene CD4 and cancer.